269 related articles for article (PubMed ID: 27143947)
1. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.
Liu L; Lu J; Allan BW; Tang Y; Tetreault J; Chow CK; Barmettler B; Nelson J; Bina H; Huang L; Wroblewski VJ; Kikly K
J Inflamm Res; 2016; 9():39-50. PubMed ID: 27143947
[TBL] [Abstract][Full Text] [Related]
2. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.
Steere B; Beidler C; Martin A; Bright S; Kikly K; Benschop RJ
J Pharmacol Exp Ther; 2023 Nov; 387(2):180-187. PubMed ID: 37714687
[TBL] [Abstract][Full Text] [Related]
3. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
Oliveira DG; Faria R; Torres T
Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
[TBL] [Abstract][Full Text] [Related]
4. Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases.
Akhter S; Tasnim FM; Islam MN; Rauf A; Mitra S; Emran TB; Alhumaydhi FA; Khalil AA; Aljohani ASM; Al Abdulmonem W; Thiruvengadam M
Curr Pharm Des; 2023; 29(26):2078-2090. PubMed ID: 37670700
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-17 family members in health and disease.
Chung SH; Ye XQ; Iwakura Y
Int Immunol; 2021 Nov; 33(12):723-729. PubMed ID: 34611705
[TBL] [Abstract][Full Text] [Related]
6. Cerebral Tumefactive Inflammatory Lesion Occurrence During Ixekizumab Treatment in a Patient With Active Psoriatic Arthritis.
Marangi A; Benvenuti F; Mazzai L; Riva G; Polo D; Franceschetti I; De Sandre P; Zanusso MA; Scanelli G; Perini F
Neurologist; 2024 Jan; ():. PubMed ID: 38251684
[TBL] [Abstract][Full Text] [Related]
7. New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
Saviano A; Manosour AA; Raucci F; Merlino F; Marigliano N; Schettino A; Wahid M; Begum J; Filer A; Manning JE; Casillo GM; Piccolo M; Ferraro MG; Marzano S; Russomanno P; Bellavita R; Irace C; Amato J; Alfaifi M; Rimmer P; Iqbal T; Pieretti S; Vellecco V; Caso F; Costa L; Giacomelli R; Scarpa R; Cirino G; Bucci M; McGettrick HM; Grieco P; Iqbal AJ; Maione F
Ann Rheum Dis; 2023 Nov; 82(11):1415-1428. PubMed ID: 37580108
[TBL] [Abstract][Full Text] [Related]
8. Ixekizumab and herpes zoster in an erythrodermic patient.
Pruneda CC; Austin BA; Wallis DT; Paulger BR; Tarbox MB
Proc (Bayl Univ Med Cent); 2020 Jul; 33(3):417-418. PubMed ID: 32675970
[TBL] [Abstract][Full Text] [Related]
9. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential.
Kellner H
Ther Adv Musculoskelet Dis; 2013 Jun; 5(3):141-52. PubMed ID: 23858337
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-17 Cytokines and Receptors: Potential Amplifiers of Tendon Inflammation.
Mimpen JY; Snelling SJB; Carr AJ; Dakin SG
Front Bioeng Biotechnol; 2021; 9():795830. PubMed ID: 35004653
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα.
Tittes J; Brell J; Fritz P; Jonak C; Stary G; Ressler JM; Künig S; Weninger W; Stöckl J
Dermatol Ther (Heidelb); 2024 Mar; 14(3):613-626. PubMed ID: 38459237
[TBL] [Abstract][Full Text] [Related]
12. Engineering a variant of IL-17RA with high binding affinity to IL-17A for optimized immunotherapy.
Armaghan F; Hajihassan Z
Biotechnol Rep (Amst); 2021 Dec; 32():e00682. PubMed ID: 34765462
[TBL] [Abstract][Full Text] [Related]
13. Ixekizumab-induced urticarial drug eruption.
Kaneoka A; Saito-Sasaki N; Okada E; Sawada Y
Skin Health Dis; 2023 Oct; 3(5):e271. PubMed ID: 37799352
[TBL] [Abstract][Full Text] [Related]
14. Blocking IL-17A prevents oxycodone-induced depression-like effects and elevation of IL-6 levels in the ventral tegmental area and reduces oxycodone-derived physical dependence in rats.
Inan S; Meissler JJ; Bessho S; Wiah S; Tukel C; Eisenstein TK; Rawls SM
Brain Behav Immun; 2024 Mar; 117():100-111. PubMed ID: 38199516
[TBL] [Abstract][Full Text] [Related]
15. "Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A".
Fischman S; Levin I; Rondeau JM; Štrajbl M; Lehmann S; Huber T; Nimrod G; Cebe R; Omer D; Kovarik J; Bernstein S; Sasson Y; Demishtein A; Shlamkovich T; Bluvshtein O; Grossman N; Barak-Fuchs R; Zhenin M; Fastman Y; Twito S; Vana T; Zur N; Ofran Y
Commun Biol; 2023 Sep; 6(1):997. PubMed ID: 37773269
[TBL] [Abstract][Full Text] [Related]
16. Multiple Mucosal Ulcers Induced by Ixekizumab: A Case Report.
Zheng C; He X; Tang X
Ann Otol Rhinol Laryngol; 2024 May; ():34894241254431. PubMed ID: 38742650
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib combined with local low-dose ixekizumab injection benefits those with peripheral psoriatic arthritis.
Xia R; Zhang W; Hang J; Yin Z
J Biomed Res; 2023 Oct; 38(1):92-94. PubMed ID: 37885297
[No Abstract] [Full Text] [Related]
18. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
[TBL] [Abstract][Full Text] [Related]
19. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
